TP53 and neoplasm: Loss or mutation of p53 disrupts DNA-damage sensing, cell-cycle checkpoints, apoptosis, and tumor–microenvironment (TME) crosstalk, thereby influencing intrinsic tumor fitness and the likelihood of benefit from systemic therapies.